Information Provided By: 
Fly News Breaks for December 7, 2015
BLUE, ONCE
Dec 7, 2015 | 09:25 EDT
Roth Capital analyst Elemer Piros said the primate data presented by Spark Therapeutics (ONCE) at the American Society of Hematology meeting was "very encouraging" and cautioned investors not to lose sight, in the wake of reactions to bluebird bio's (BLUE) results, that Spark is the first and only gene therapy company with success in a controlled pivotal trial. Piros reiterates a Buy rating and $90 price target on Spark shares.
News For ONCE;BLUE From the Last 2 Days
There are no results for your query ONCE;BLUE
